FDA APPROVES THE FIRST TARGETED THERAPY TO TREAT A RARE MUTATION IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
FDA approved on Thursday avapritinib (Ayvakit—Blueprint Medicines) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation. The approval includes GIST that includes a PDGFRA D842V mutation, the most common exon 18 mutation. “GIST harboring a PDGFRA exon 18 mutation do […]
